Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A phase 2 trial of Camizestrant and Atirmociclib in advanced solid tumours, run by AstraZeneca, now recruiting.
Overview
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer is a phase 2 interventional study registered as NCT07427394 by AstraZeneca, with 24 participants planned, started 2026-05-06 and due to reach its primary completion in 2027-12-28. Interventions recorded: Camizestrant and Atirmociclib.
Similar pages
not linked directly; found by shared links- TrialA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Shares Camizestrant, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares Atirmociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialA Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Shares Atirmociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares Camizestrant, AstraZeneca and the tag pipeline.
- TrialStudy of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.